The instruction
for medical use
of TP Bronhipret® medicine
the Trade name
of Bronhipret® of TP
the International unlicensed name
Is not present.
The dosage form
of the Tablet, coated
Structure
One tablet contains
active agents: a thyme of a grass of extract dry - 160.00 mg,
a primrose of a root of extract dry - 60.00 mg,
excipients: lactoses monohydrate, glucose syrup (dry), K25 povidone, krospovidon, silicon dioxide colloidal anhydrous, cellulose microcrystalline, magnesium stearate, talc.
structure of a cover: the titan dioxide (171), talc, a chlorophyll powder (E 141),
Riboflavinum (E 101), is sawn through glycol, a gipromelloza, polyacrylate dispersion (30%), dimetikon, fragrance of a peppermint, sodium saccharin
the Description
of the Tablet of green color, round shape with a biconvex semi-gloss surface, with a diameter from 10.1 to 10.3 mm, from 5.4 to 6.0 mm high.
Pharmacotherapeutic group
Drugs for elimination of symptoms of cold and cough. Combination of expectorant drugs.
The code of automatic telephone exchange R05CA10
the Pharmacological
Pharmacokinetics Action properties of the drug Bronhipret® TP of a tablet, is result of aggregate effect of its components therefore carrying out kinetic researches is not possible.
The pharmacodynamics
of Bronhipret® of TP of a tablet renders expectorant, anti-inflammatory, sekretolitichesky, broncholitic action.
Extract of a grass of a thyme (Thymi herba) has sekretolitichesky and broncholitic effect which are caused by existence in drug of essential oils and flavonoids. Also the antibacterial effect of drug caused by a timolovy component of essential oil was confirmed.
Extract of a root of a primrose (Primulae radix) has sekretolitichesky properties which it is possible to charge to primrose saponins. As far as we know at the moment, the sekretolitichesky effect is reached by means of the reflex mechanism at action on sensitive nerve terminations of a digestive tract.
Indications
- as expectorant at treatment of acute and chronic inflammatory respiratory diseases,
the Routes of administration and doses which are followed by cough and formation of a phlegm (bronchitis, a tracheobronchitis, tracheitis).
Adults and teenagers are more senior than 12 years: on 1 tablet 3 times in day
of the Tablet in a cover should be swallowed, without chewing, before food. To wash down with a small amount of liquid.
Side effects
Very seldom
- reactions of hypersensitivity, including short wind, skin rash, a small tortoiseshell, puffiness of the face, mouth and/or throat.
Are possible
- digestive tract spasms, nausea, vomiting, diarrhea
in case of any of the listed side effects stop administration of drug and see a doctor. The doctor can define gravity and need of further actions.
Contraindications
- the increased hypersensitivity to drug components, to an ivy, a thyme or other plants of the Lamiaceae family (mint family), a birch, a wormwood, a celery
- children's age up to 12 years
Medicinal interactions
At the moment of interaction with other medicines are unknown.
In case the patient along with this drug accepts other medicines or recently, before purpose of Bronhipreta® of TP applied any drugs, it is necessary to report about it to the attending physician.
Special instructions
Use for patients with diabetes
1 tablet Bronhipret® TP (single dose) contains on average 0.02 grain units of glucose.
Бронхипрет® TP of a tablet contain lactose therefore it is not recommended to patients with hereditary intolerance of a galactose, insufficiency of lactase or malabsorption of glucose and a galactose.
If at use of drug within more than 1 week the symptoms of a disease remain, or such symptoms as an asthma, the increased temperature, a purulent phlegm or a phlegm with blood are observed it is necessary to see a doctor immediately.
Pregnancy and lactation
Due to the lack of clinical data on safety of drug during pregnancy and a lactation, is not recommended to apply Bronhipret® of TP during pregnancy and a lactation.
There Is no feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms data about influences of drug on ability to run transport or potentially dangerous mechanisms.
Overdose
At overdose gastric disorders, vomiting and diarrhea are possible. In case of overdose it is necessary to stop administration of drug and to consult with the doctor.
A form of release and packing
On 20 tablets in blister strip packaging (blister) from aluminum foil (bottom side) and films from PVC, PE, PVDH (top side).
On 1 blister strip packaging (blister) together with the instruction for medical use in the state and Russian languages is placed in a pack from cardboard.
To Store storage conditions in the dry, protected from light place, at a temperature not above 25ºС.
To store out of children's reach!
Period of storage
3 years.
Not to use after term
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)
Representation Bionorica SE/Bionorik XIE /
Almaty, Central post office, p.o. box No. 200, ph. 250-93-99
e-mail specified on packing Prescription status Without prescription the Producer Bionorika XIE, D-92308 of Noymarkt / Germany the Owner of the registration certificate Bionorika XIE, Germany: info@bionorica.kz
for medical use
of TP Bronhipret® medicine
the Trade name
of Bronhipret® of TP
the International unlicensed name
Is not present.
The dosage form
of the Tablet, coated
Structure
One tablet contains
active agents: a thyme of a grass of extract dry - 160.00 mg,
a primrose of a root of extract dry - 60.00 mg,
excipients: lactoses monohydrate, glucose syrup (dry), K25 povidone, krospovidon, silicon dioxide colloidal anhydrous, cellulose microcrystalline, magnesium stearate, talc.
structure of a cover: the titan dioxide (171), talc, a chlorophyll powder (E 141),
Riboflavinum (E 101), is sawn through glycol, a gipromelloza, polyacrylate dispersion (30%), dimetikon, fragrance of a peppermint, sodium saccharin
the Description
of the Tablet of green color, round shape with a biconvex semi-gloss surface, with a diameter from 10.1 to 10.3 mm, from 5.4 to 6.0 mm high.
Pharmacotherapeutic group
Drugs for elimination of symptoms of cold and cough. Combination of expectorant drugs.
The code of automatic telephone exchange R05CA10
the Pharmacological
Pharmacokinetics Action properties of the drug Bronhipret® TP of a tablet, is result of aggregate effect of its components therefore carrying out kinetic researches is not possible.
The pharmacodynamics
of Bronhipret® of TP of a tablet renders expectorant, anti-inflammatory, sekretolitichesky, broncholitic action.
Extract of a grass of a thyme (Thymi herba) has sekretolitichesky and broncholitic effect which are caused by existence in drug of essential oils and flavonoids. Also the antibacterial effect of drug caused by a timolovy component of essential oil was confirmed.
Extract of a root of a primrose (Primulae radix) has sekretolitichesky properties which it is possible to charge to primrose saponins. As far as we know at the moment, the sekretolitichesky effect is reached by means of the reflex mechanism at action on sensitive nerve terminations of a digestive tract.
Indications
- as expectorant at treatment of acute and chronic inflammatory respiratory diseases,
the Routes of administration and doses which are followed by cough and formation of a phlegm (bronchitis, a tracheobronchitis, tracheitis).
Adults and teenagers are more senior than 12 years: on 1 tablet 3 times in day
of the Tablet in a cover should be swallowed, without chewing, before food. To wash down with a small amount of liquid.
Side effects
Very seldom
- reactions of hypersensitivity, including short wind, skin rash, a small tortoiseshell, puffiness of the face, mouth and/or throat.
Are possible
- digestive tract spasms, nausea, vomiting, diarrhea
in case of any of the listed side effects stop administration of drug and see a doctor. The doctor can define gravity and need of further actions.
Contraindications
- the increased hypersensitivity to drug components, to an ivy, a thyme or other plants of the Lamiaceae family (mint family), a birch, a wormwood, a celery
- children's age up to 12 years
Medicinal interactions
At the moment of interaction with other medicines are unknown.
In case the patient along with this drug accepts other medicines or recently, before purpose of Bronhipreta® of TP applied any drugs, it is necessary to report about it to the attending physician.
Special instructions
Use for patients with diabetes
1 tablet Bronhipret® TP (single dose) contains on average 0.02 grain units of glucose.
Бронхипрет® TP of a tablet contain lactose therefore it is not recommended to patients with hereditary intolerance of a galactose, insufficiency of lactase or malabsorption of glucose and a galactose.
If at use of drug within more than 1 week the symptoms of a disease remain, or such symptoms as an asthma, the increased temperature, a purulent phlegm or a phlegm with blood are observed it is necessary to see a doctor immediately.
Pregnancy and lactation
Due to the lack of clinical data on safety of drug during pregnancy and a lactation, is not recommended to apply Bronhipret® of TP during pregnancy and a lactation.
There Is no feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms data about influences of drug on ability to run transport or potentially dangerous mechanisms.
Overdose
At overdose gastric disorders, vomiting and diarrhea are possible. In case of overdose it is necessary to stop administration of drug and to consult with the doctor.
A form of release and packing
On 20 tablets in blister strip packaging (blister) from aluminum foil (bottom side) and films from PVC, PE, PVDH (top side).
On 1 blister strip packaging (blister) together with the instruction for medical use in the state and Russian languages is placed in a pack from cardboard.
To Store storage conditions in the dry, protected from light place, at a temperature not above 25ºС.
To store out of children's reach!
Period of storage
3 years.
Not to use after term
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)
Representation Bionorica SE/Bionorik XIE /
Almaty, Central post office, p.o. box No. 200, ph. 250-93-99
e-mail specified on packing Prescription status Without prescription the Producer Bionorika XIE, D-92308 of Noymarkt / Germany the Owner of the registration certificate Bionorika XIE, Germany: info@bionorica.kz
Related Products
